Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)

NCT01994837 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT01994837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01994837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2013
Completion date
December 31, 2014
Enrollment
32 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia, acute myeloid leukemia, aml